Delivery Order SPE2DB22D3301-SPE2DB24FY9BD
Award Date
6/21/24
Potential Completion Date
7/15/24
Potential Value
$69K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to AmerisourceBergen Drug Corp Corporate Office Division is a delivery order valued at $57,795.20 for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract is a firm fixed-price agreement with the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of September 3, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award, which is not set aside for any specific business type....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $46,236.16, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The order has an ultimate completion date of August 14, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded several federal contracts and indefinite delivery contracts (IDCs) by various defense and...
This is a federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at $46,236.16, is a Delivery Order from the Defense Logistics Agency (DLA) to provide OCREVUS 300 MG/10 ML VIAL 10ML. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
This federal contract award, valued at $57,795.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is a Delivery Order for the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML, with a completion date of June 4, 2024. Amerisourcebergen Drug Corp's Corporate Office Division is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $119,585.40 and a completion date of December 26, 2024. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $96,154.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a medical product, with a completion date of February 14, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $60,096.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a fixed price and a completion date of February 18, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, with an ID of SPE2DX15D1053|SPE2DX24F6NRV, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract, valued at $46,236.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract is a Firm Fixed Price Delivery Order with a completion date of July 5, 2024. Amerisourcebergen, as a major pharmaceutical distribution company, holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $47,834.16 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of December 16, 2024 and does not include any set-aside requirements, indicating open competition. AmerisourceBergen holds a significant $999,999,999...